Get the latest Science News and Discoveries

First in-human investigator-initiated clinical trial to launch for refractory prostate cancer patients - EurekAlert


Osaka University is starting a Phase I clinical trial (first in human) for refractory prostate cancer using an astatine-labeled drug ([At-211]PSMA-5). This trial aims to evaluate the safety, pharmacokinetics, and efficacy of the new alpha therapy. Previous trials for thyroid cancer have been successful. The trial addresses the high unmet needs of prostate cancer patients and leverages Japan's ability to manufacture astatine. This innovative therapy promises fewer side effects and no need for hospitalization, potentially benefiting patients globally.

None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of Human

Human

Photo of investigator

investigator

Photo of EurekAlert

EurekAlert

Related news:

News photo

Valentin Fuster, MD, PhD, receives prestigious award from World Heart Federation - EurekAlert

News photo

Scientists uncover a multibillion-year epic written into the chemistry of life - EurekAlert

News photo

Biodiversity in the margins: Merging farmlands affects natural pest control - EurekAlert